‘Contemplation’

Publication
Article
OncologyONCOLOGY Vol 20 No 14
Volume 20
Issue 14

I was diagnosed with ovarian cancer seven and a half years ago. The news was overwhelming. The painting depicts how I began; absorbing the shock and then going through the feelings of loss, bewilderment, and fear of the unknown.

I was diagnosed with ovarian cancer seven and a half years ago. The news was overwhelming. The painting depicts how I began; absorbing the shock and then going through the feelings of loss, bewilderment, and fear of the unknown.

But very quickly the practicalities take over: hospital, chemotherapy, scans. Wherever I went, whichever hospital or clinic, there was nothing but kindness, and this, together with the love and support of my family and friends, made this period not only bearable but illuminating as well.

And then, in time, everyday life (which is beyond the window in this picture) resumes. But it seems that the colors are brighter, the focus is sharper. And I have always kept in mind, like an internal beacon, lines from Robert Frost's poem:

"But I have promises to keep, And miles to go before I sleep."

—Bobbie Redemer

*Award winner (global) in the 2006 Lilly Oncology on Canvas art competition and exhibition. The global winners were announced November 3. US winners were announced December 5. The biennial competition is open to any person diagnosed with cancer; family members, friends, and caregivers; health-care professionals; plus artists and art students. Entrants are asked to express, through art and in narrative, the life-affirming changes that give their cancer journey meaning. More than 2,000 entries from 43 countries were received, including this painting by Bobbie Redemer of Berkshire, England. The program was created by Eli Lilly and Company.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.